Bausch + Lomb (BLCO) Projected to Post Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect Bausch + Lomb to post earnings of $0.35 per share and revenue of $1.3834 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 8:00 AM ET.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO opened at $17.04 on Tuesday. The stock’s fifty day simple moving average is $16.99 and its 200 day simple moving average is $15.77. The stock has a market capitalization of $6.04 billion, a price-to-earnings ratio of -19.59, a PEG ratio of 0.99 and a beta of 0.61. The company has a quick ratio of 0.98, a current ratio of 1.51 and a debt-to-equity ratio of 0.76. Bausch + Lomb has a 52-week low of $10.45 and a 52-week high of $17.86.

Wall Street Analyst Weigh In

BLCO has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a research note on Wednesday, January 21st. Wells Fargo & Company raised their target price on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, November 14th. Barclays boosted their price target on shares of Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Friday, October 31st. Citigroup raised Bausch + Lomb from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. increased their target price on shares of Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $17.42.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of BLCO. Northwestern Mutual Wealth Management Co. boosted its holdings in Bausch + Lomb by 729.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after purchasing an additional 2,042 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Bausch + Lomb by 104.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Bausch + Lomb by 31.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after acquiring an additional 1,403 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Bausch + Lomb during the 3rd quarter valued at about $170,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $200,000. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.